Objective To analyze the clinical safety of allergic rhinitis (AR) patients with sublingual immunotherapy (SLIT) and simultaneous vaccination of novel coronavirus.

Methods A total of 441 patients with AR treated by SLIT and simultaneous vaccination of novel coronavirus were selected as research objects, and incidence of complications related to vaccination was observed.

Results Among the 441 AR patients, 51 adult patients received the first dose of novel coronavirus vaccine in the incremental period of SLIT, but there were 2 cases of local urticaria, 1 case of low fever and 2 cases of fatigue and pain after the vaccination, and the incidence of adverse reactions was 9.8%(5/51); a total of 390 patients received the first dose of novel coronavirus vaccine in the maintenance period of SLIT, but there was 1 case with stuffy and running nose after vaccination, and the incidence of adverse reactions was 0.26%(1/390). One of 441 AR patients had general fatigue after receiving the second dose of novel coronavirus vaccine, and the incidence of adverse reactions was 0.23%(1/441); a total of 423 AR patients had no adverse reactions after receiving the third dose of novel coronavirus vaccine.

Conclusion Under the normalization management for epidemic situation of the Coronavirus Disease 2019, it is recommended that AR patients should be inoculated with novel coronavirus vaccine in the maintenance period of specific immunotherapy to avoid vaccination in the incremental period, so as to reduce the incidence of adverse reactions. If adverse reactions occur after receiving the first dose of novel coronavirus vaccine, specific immunotherapy should be suspended when the second and third doses of novel coronavirus vaccine are inoculated, and specific immunotherapy should be carried out after there are no adverse reactions, so as to avoid the impact of multiple immune responses on the internal environment and improve the safety of simultaneous treatment of multiple immune schemes.